ORLANDO, Fla., May 8, 2013 - Researchers discovered that small pieces of genetic material called microRNAs link the two defining characteristics of fit muscles: the ability to burn sugar and fat and the ability to switch between slow- and fast-twitch muscle fibers. The team used two complementary mouse models--the "marathon mouse" and the "couch potato mouse"--to make this discovery. But what's more, they also found that active people have higher levels of one of these microRNAs than sedentary people. These findings, published May 8 in The Journal of Clinical Investigation, suggest microRNAs could be targeted for the development of new medical interventions aimed at improving muscle fitness in people with chronic illness or injury.
"In this study, we wanted to determine, on a molecular level, what makes a muscle fit during development or following exercise. This information is relevant to our efforts to improve muscle fitness in many health conditions, such as aging, cancer, and heart failure. These findings may also prove useful for our active members of the military, who become 'detrained' during injury and recovery time," said Daniel P. Kelly, M.D., director of Sanford-Burnham's Diabetes and Obesity Research Center and senior author of the study.
Marathon vs. couch potato mice
Fit muscle is known for its ability to do two things: 1) burn fat and sugars and 2) switch between slow-twitch and fast-twitch muscles. According to Kelly, muscle fitness only occurs if both are functioning properly.
Increased muscle endurance cannot occur without boosting both of these muscle components. Kelly and his team set out to determine what connects muscle metabolism and structure. To do this, they turned to two different mouse models, each specially engineered to produce distinct but related proteins that turn muscle-specific genes on and off.
The first model, dubbed the "marathon mouse," has a muscle-gene regulator called PPARβ/δ. These mice can run much further than normal mice. The second model, known as the "couch potato mouse," produces a different muscle-gene regulator, called PPARα. These mice are able to burn a lot of fuel, but they can't run very far.
MicroRNAs in muscle fitness
To identify the link between muscle metabolism and muscle fiber type-switching, Kelly's team compared the molecular differences between these two disparate mouse models.
First, the team found that PPARα couch potato mice have the optimal metabolic switch, but lack the muscle fiber switch. In contrast, PPARβ/δ marathon mice have the whole package necessary for muscle fitness.
The two mouse models also differed in molecular profiling, according to this study. The team discovered that marathon mice produce certain microRNAs that are capable of activating the fiber switch. By comparison, this same circuitry is suppressed in couch potato mice.
Digging a little deeper, Kelly's team determined that PPARβ/δ is connected to microRNAs via an intermediary called estrogen-related receptor (ERRγ). This protein collaborates with PPARβ/δ to turn on microRNAs. That's why marathon mice are fitter and have more type I muscle fibers than couch potato mice--their PPARβ/δ and ERRγ induce the right microRNAs.
Muscle-boosting potential for patients
To determine if their findings were relevant to human health, Kelly and his team worked with Steven R. Smith, M.D., director of the Florida Hospital--Sanford-Burnham Translational Research Institute for Metabolism and Diabetes. From there, the team obtained muscle tissue from sedentary people (those who don't exercise regularly) and active people in good shape.
Sure enough, ERRγ and one of the microRNAs elevated in PPARβ/δ marathon mice were also increased in active people, but not the sedentary group.
"We're now conducting additional human studies to further investigate the ERRγ-microRNA circuit as a potential avenue for improving fitness in people with chronic illness or injury," Kelly said. "For example, next we want to know what happens to this circuit during exercise and what effect it has on the cardiovascular system."
This research was funded by the U.S. National Institutes of Health (grants RO1DK045416, R01DK095686, R01AR41928, R01AG030226), American Heart Association, Robert A. Welch Foundation, Jon Holden DeHaan Foundation, Fondation Leducq TransAtlantic Network of Excellence in Cardiovascular Research Program, ERC, Ecole Polytechnique Fédérale de Lausanne, Swiss National Science Foundation, and Novartis Clinical Innovation Fund.
The study was co-authored by Zhenji Gan, Sanford-Burnham; John Rumsey, Sanford-Burnham; Bethany C. Hazen, The Scripps Research Institute; Ling Lai, Sanford-Burnham; Teresa C. Leone, Sanford-Burnham; Rick B. Vega, Sanford-Burnham; Hui Xie, Translational Research Institute for Metabolism and Diabetes, Florida Hospital; Kevin E. Conley, University of Washington Medical Center; Johan Auwerx, École Polytechnique Fédérale de Lausanne; Steven R. Smith, Sanford-Burnham, Translational Research Institute for Metabolism and Diabetes, Florida Hospital; Eric N. Olson, University of Texas Southwestern Medical Center; Anastasia Kralli, The Scripps Research Institute; and Daniel P. Kelly, Sanford-Burnham.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), California and Orlando (Lake Nona), Florida. For more information, visit us at sanfordburnham.org.